According to Boehringer Ingelheim, the FDA has approved the company’s Spiriva Respimat tiotropium bromide inhalation soft mist inhaler for the treatment of COPD. In August 2014, the FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted in favor of approval of the SMI. The company said that Spiriva Respimat should be available in January 2015.
BI Pharmaceuticals Senior VP, Medicine & Regulatory Affairs, Sabine Luik commented, “Spiriva Respimat offers a new choice between a mist and dry powder inhaler for tiotropium. Already approved in 85 countries around the world, Spiriva Respimat reflects our scientific heritage as an industry leader in discovering and developing new treatment options for the COPD community.”
Read the BI press release.
